Taken together, our data indicate that human T cells gene-modified to secrete high-affinity monomeric decoys of CD47 will not be depleted in treated patients due to other “don’t eat me” signals at play, and that the coadministration of tumor-targeted Abs can favorably reprogram the TME and harness phagocytes against tumor cells for improved clinical outcome. The gene discussed is CD47; the disease is neoplasm.